Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

VIDEO: New PLATINUM Diversity Data Shows Early DAPT Cessation OK in Minorities With New Generation Stent

Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...
VIDEO: Early Discontinuation of DAPT in High Bleeding Risk Patients With the Synergy Stent

Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the cardiac catheterization laboratories at NewYork-Presbyterian (NYP) Hospital...
VIDEO: TWILIGHT Trial Shows Benefit to Ticagrelor Monotherapy After Stent Implantation

Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of...
VIDEO: Overview of Short DAPT in High-risk Bleeding Patients Who Receive Stents

American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-antiplatelet therapy (DAPT) in high-risk bleeding patient

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients.

Feature | Stents Peripheral | November 06, 2019 | Dave Fornell, Editor

No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES...

Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA

News | Peripheral Artery Disease (PAD) | November 06, 2019

Positive Data for the Ranger Drug-coated Balloon and Eluvia Vascular Stent

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-...

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)

Feature | TCT | November 04, 2019 | Dave Fornell, Editor

6 Hot Topics in Interventional Cardiology at TCT 2019

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual...

Videos | Antiplatelet and Anticoagulation Therapies | October 17, 2019

VIDEO: New PLATINUM Diversity Data Shows Early DAPT Cessation OK in Minorities With New Generation Stent

Roxana Mehran, M.D., FACC, FACP,...

News | Stents Drug Eluting | October 11, 2019

Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure

October 11, 2019 — The ultra-thin Supraflex drug-...

Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019

VIDEO: Early Discontinuation of DAPT in High Bleeding Risk Patients With the Synergy Stent

Ajay J. Kirtane, M.D., associate...

Videos | Antiplatelet and Anticoagulation Therapies | October 10, 2019

VIDEO: TWILIGHT Trial Shows Benefit to Ticagrelor Monotherapy After Stent Implantation

Roxana Mehran, M.D.,...

Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019

VIDEO: Overview of Short DAPT in High-risk Bleeding Patients Who Receive Stents

American Heart Association President ...

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

Feature | Cath Lab | October 03, 2019

Left Main Treated With PCI or CABG Have Similar Outcomes at Five Years

October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with...